secwatch.observer — SEC 8-K summary
======================================

Issuer:     NexImmune, Inc. (—)
CIK:        0001538210
Form:       8-K
Filed at:   2024-04-05T23:59:59+00:00
Accession:  0001193125-24-088454
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

NexImmune CFO Timothy Stover resigns; Albert Marchio named interim CFO
----------------------------------------------------------------------

- Timothy Stover, principal financial and accounting officer, resigns effective April 16, 2024; not due to disagreement.
- Albert N. Marchio II appointed Interim CFO and principal financial/accounting officer, effective upon Stover's resignation.
- Marchio, 71, has 32 years pharma industry experience; currently a consultant via Danforth Advisors LLC.
- Danforth Advisors will provide interim CFO services under a consulting agreement with hourly rate and indemnification terms.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1538210/000119312524088454/0001193125-24-088454-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1538210/000119312524088454/d818104d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-088454

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer